JOURNAL ARTICLE
REVIEW
NovoSeven: mode of action and use in acquired haemophilia.
Intensive Care Medicine 2002 October
Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of spontaneous and surgical bleeding in patients with haemophilia A or B with antibodies to factors VIII or IX (FVIII or FIX) worldwide, and in patients with acquired haemophilia in Europe. In vitro cell models have demonstrated that rFVIIa can bind to activated platelets and generate small amounts of Fxa, independent of the presence of tissue factor. The amount of platelet-surface Fxa formed increases with rising concentrations of FVIIa and, at levels of rFVII a that are effective in patients, sufficient platelet surface Fxa is generated partially to restore platelet surface thrombin generation. Acquired haemophilia is a rare but potentially life-threatening condition, caused by the autoimmune reduction of clotting factor levels as a result of the spontaneous development of auto-antibodies directed against the deficient factor. Bleeding into the skin or muscles is common in acquired haemophilia and the associated mortality rate is approximately 20%. rFVIIa has reported efficacy in the treatment of major bleeding episodes in patients with acquired haemophilia, which may be explained by its distinct mechanism of action that induces haemostasis at the site of injury, independent of the presence of FVIII or FIX. Also, the localisation of the action of rFVIIa at the site of injury may explain why it is well tolerated in these patients.
Full text links
Trending Papers
Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!Liver International : Official Journal of the International Association for the Study of the Liver 2023 June
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.Nature Reviews. Rheumatology 2023 May 10
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app